Robert Fridman, DPM
Foot & Ankle Surgery · Bronx, NYNPI 1811938707
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,283 of the $46,896 with a category attached, or 66.7%. 19 manufacturers reported payments, led by Reprise Biomedical, Inc. at 29.2% of the total. Reporting peaked in 2019 at $19,671 and has fallen 93.4% since, to $1,302 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $689.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reprise Biomedical, Inc.$14K
- Miromatrix Medical Inc.$12K
- Smith+Nephew$12K
- Integra Lifesciences Corporation$4K
- Royal Biologics, Inc.$1K
- Tenex Health Inc.$1K
- plus $3K from 13 others
Across 4 payments — averaging $6438.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Royal Biologics, Inc.$26K
What the payments were for
- Consulting fees$31,28367%
- Speaking & faculty fees$9,87521%
- Travel & lodging$2,8476%
- Food & beverage$2,8916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reprise Biomedical, Inc. | 6 | $13,689 |
| Miromatrix Medical Inc. | 3 | $12,204 |
| Smith+Nephew | 24 | $11,547 |
| Integra Lifesciences Corporation | 8 | $3,813 |
| Royal Biologics, Inc. | 3 | $1,200 |
| Tenex Health Inc. | 2 | $1,162 |
| Sweetbio, Inc. | 1 | $1,050 |
| Kerecis Limited | 5 | $837 |
| Crossroads Extremity Systems, LLC | 2 | $219 |
| ETS Wound Care LLC | 1 | $198 |
| Polarityte, Inc. | 2 | $196 |
| Osiris Therapeutics Inc. | 3 | $174 |
| Abbott | 1 | $129 |
| Melinta Therapeutics, LLC | 1 | $123 |
| Baxter Healthcare | 1 | $123 |
| In2bones USA, LLC | 1 | $106 |
| Stryker | 2 | $90 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Miroderm$12,204
- Santyl$5,032
- REGRANEX$3,883
- COLLAGENASE SANTYL$3,800
- Kerecis SurgiClose$3,118
- Oasis$3,013
- INTEGRA$2,800
- ADVANCED WOUND CARE$2,200
- VERSAJET II$1,400
- NEURAGEN$1,400
- Fibrinet$800
- Kerecis GraftGuide$780
- CryoCord$400
- CYTAL$230
- CoLink$213
- MIRRAGEN ADVANCED WOUND MATRIX$198
- MIRO3D$189
- MIRO3D FIBERS$189
- Supera peripheral stent system$129
- Baxdela$123
How this compares
$46,896 in reported general payments places this provider in the 95th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 16 | $4,555 |
| Ammonium Lactate | 146 | $3,216 |
| Ciclopirox | 17 | $1,987 |
| CiclopiroxCiclopirox Olamine | 23 | $691 |
| Gabapentin | 51 | $632 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $616 |
| Doxycycline Hyclate | 27 | $274 |
| Terbinafine Hcl | 22 | $255 |
| Meloxicam | 62 | $177 |
| Colchicine | 11 | $149 |
| Mupirocin | 11 | $79 |
| Cephalexin | 13 | $72 |
| Fluconazole | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $11,547 | $4,55516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 foot & ankle surgery providers in New York.
Other foot & ankle surgery in Bronx
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$597K
- John KennedyNew York$534K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$328K
- Stuart MogulNew York$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.